These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30035061)

  • 1. Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review.
    Suen PK; Qin L
    J Orthop Translat; 2016 Jan; 4():1-13. PubMed ID: 30035061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
    Ardawi MS; Rouzi AA; Al-Sibiani SA; Al-Senani NS; Qari MH; Mousa SA
    J Bone Miner Res; 2012 Dec; 27(12):2592-602. PubMed ID: 22836717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced Sirtuin1 expression at the femoral neck in women who sustained an osteoporotic hip fracture.
    El-Haj M; Gurt I; Cohen-Kfir E; Dixit V; Artsi H; Kandel L; Yakubovsky O; Safran O; Dresner-Pollak R
    Osteoporos Int; 2016 Jul; 27(7):2373-2378. PubMed ID: 26902093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sclerostin antibodies in animal models of osteoporosis.
    Ominsky MS; Boyce RW; Li X; Ke HZ
    Bone; 2017 Mar; 96():63-75. PubMed ID: 27789417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis.
    Hadaya D; Gkouveris I; Soundia A; Bezouglaia O; Boyce RW; Stolina M; Dwyer D; Dry SM; Pirih FQ; Aghaloo TL; Tetradis S
    J Bone Miner Res; 2019 Jan; 34(1):171-181. PubMed ID: 30184271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Therapy of Osteoporosis: What's New?
    Iolascon G; Moretti A; Toro G; Gimigliano F; Liguori S; Paoletta M
    Clin Interv Aging; 2020; 15():485-491. PubMed ID: 32273690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.
    Shah AD; Shoback D; Lewiecki EM
    Int J Womens Health; 2015; 7():565-80. PubMed ID: 26082665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging anabolic agents in the treatment of osteoporosis.
    Lovato C; Lewiecki EM
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):247-257. PubMed ID: 28756709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-sclerostin - is there an indication?
    Larsson S
    Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
    Stevenson M; Davis S; Lloyd-Jones M; Beverley C
    Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper.
    Goldhahn J; Féron JM; Kanis J; Papapoulos S; Reginster JY; Rizzoli R; Dere W; Mitlak B; Tsouderos Y; Boonen S
    Calcif Tissue Int; 2012 May; 90(5):343-53. PubMed ID: 22451221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of the Potential Application of Osteocyte-Related Biomarkers, Fibroblast Growth Factor-23, Sclerostin, and Dickkopf-1 in Predicting Osteoporosis and Fractures.
    Ramli FF; Chin KY
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32155909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of osteoporosis medications on fracture healing.
    Hegde V; Jo JE; Andreopoulou P; Lane JM
    Osteoporos Int; 2016 Mar; 27(3):861-871. PubMed ID: 26419471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating osteoporosis to prevent fractures: current concepts and future developments.
    Lorentzon M
    J Intern Med; 2019 Apr; 285(4):381-394. PubMed ID: 30657216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing?
    Ha KY; Park KS; Kim SI; Kim YH
    Osteoporos Int; 2016 Feb; 27(2):483-8. PubMed ID: 26202489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriate models for novel osteoporosis drug discovery and future perspectives.
    Gennari L; Rotatori S; Bianciardi S; Gonnelli S; Nuti R; Merlotti D
    Expert Opin Drug Discov; 2015; 10(11):1201-16. PubMed ID: 26292627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Wnt signaling pathway for the development of novel therapies for osteoporosis.
    Yavropoulou MP; Papapoulos SE
    Expert Rev Endocrinol Metab; 2010 Sep; 5(5):711-722. PubMed ID: 30764023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.
    McClung MR
    Ther Adv Musculoskelet Dis; 2017 Oct; 9(10):263-270. PubMed ID: 28974988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fracture healing in osteoporotic fractures: is it really different? A basic science perspective.
    Giannoudis P; Tzioupis C; Almalki T; Buckley R
    Injury; 2007 Mar; 38 Suppl 1():S90-9. PubMed ID: 17383490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.